Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.
Authors
Masatoshi Kudo
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan
Masatoshi Kudo , Kazuomi Ueshima , Shin Nakahira , Naoshi Nishida , Hiroshi Ida , Yasunori Minami , Takuya Nakai , Hiroshi Wada , Shoji Kubo , Kazuyoshi Ohkawa , Asahiro Morishita , Takeo Nomi , Koji Ishida , Shogo Kobayashi , Makoto Umeda , Masakatsu Tsurusaki , Yasutaka Chiba , Kenichi Yoshimura , Kazuko Sakai , Kazuto Nishio
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
UMIN 000026648
DOI
10.1200/JCO.2022.40.4_suppl.416
Abstract #
416
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.
First Author: Masatoshi Kudo
Poster
2023 ASCO Annual Meeting
Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.
First Author: Jared Cohen
Poster
2022 ASCO Annual Meeting
IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).
First Author: Arndt Vogel
Poster
2022 ASCO Annual Meeting
Multiomics profiling and association with molecular and immune features in association with benefits from immunotherapy for patients with previously treated stage IV or recurrent squamous cell lung cancer from the phase III SWOG LungMAP S1400I trial.
First Author: Edwin R. Parra